-
1
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
and RE-LY Steering Committee and Investigators
-
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al, and RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
-
(2009)
N Engl J Med.
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
Parekh, A.6
Pogue, J.7
Reilly, P.A.8
Themeles, E.9
Varrone, J.10
-
2
-
-
79957715797
-
Anticoagulant optionsVwhy the FDA approved a higher but not a lower dose of dabigatran
-
Beasley BN, Unger EF, Temple R. Anticoagulant optionsVwhy the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364:1788-1790.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1788-1790
-
-
Beasley, B.N.1
Unger, E.F.2
Temple, R.3
-
3
-
-
77953168824
-
Dabigatran etexilateVa novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
-
van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilateVa novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
-
(2010)
Thromb Haemost.
, vol.103
, pp. 1116-1127
-
-
Van Ryn, J.1
Stangier, J.2
Haertter, S.3
Liesenfeld, K.H.4
Wienen, W.5
Feuring, M.6
Clemens, A.7
-
4
-
-
77956977472
-
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial f ibrillation: An analysis of the RE-LY trial
-
and RE-LY Investigators
-
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, et al, and RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial f ibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376:975-983.
-
(2010)
Lancet.
, vol.376
, pp. 975-983
-
-
Wallentin, L.1
Yusuf, S.2
Ezekowitz, M.D.3
Alings, M.4
Flather, M.5
Franzosi, M.G.6
Pais, P.7
Dans, A.8
Eikelboom, J.9
Oldgren, J.10
-
5
-
-
80052232522
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial
-
RE-DEEM Investigators
-
Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L, RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781-2789.
-
(2011)
Eur Heart J.
, vol.32
, pp. 2781-2789
-
-
Oldgren, J.1
Budaj, A.2
Granger, C.B.3
Khder, Y.4
Roberts, J.5
Siegbahn, A.6
Tijssen, J.G.7
Van De Werf, F.8
Wallentin, L.9
-
6
-
-
77957029781
-
Dabigatran etexilate: Pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty
-
Eriksson BI, Friedman RJ. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009;15(suppl 1):25S-31S.
-
(2009)
Clin Appl Thromb Hemost.
, vol.15
, Issue.SUPPL. 1
-
-
Eriksson, B.I.1
Friedman, R.J.2
-
7
-
-
79953836474
-
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomized, double-blind, noninferiority trial
-
RE-NOVATE II Study Group
-
Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ, RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomized, double-blind, noninferiority trial. Thromb Haemost. 2011;105:721-729.
-
(2011)
Thromb Haemost.
, vol.105
, pp. 721-729
-
-
Eriksson, B.I.1
Dahl, O.E.2
Huo, M.H.3
Kurth, A.A.4
Hantel, S.5
Hermansson, K.6
Schnee, J.M.7
Friedman, R.J.8
-
8
-
-
71849117615
-
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
-
(2009)
N Engl J Med.
, vol.361
, pp. 2342-2352
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
Mismetti, P.4
Schellong, S.5
Eriksson, H.6
Baanstra, D.7
Schnee, J.8
Goldhaber, S.Z.9
Study Group, R.10
-
9
-
-
34548031359
-
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
-
DOI 10.1111/j.1365-2125.2007.02899.x
-
Stangier J, Rathgen K, Stahle H, Gansser D, RothW. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303. (Pubitemid 47283865)
-
(2007)
British Journal of Clinical Pharmacology
, vol.64
, Issue.3
, pp. 292-303
-
-
Stangier, J.1
Rathgen, K.2
Stahle, H.3
Gansser, D.4
Roth, W.5
-
11
-
-
79956087035
-
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves
-
McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011;141:1410-1416.
-
(2011)
J Thorac Cardiovasc Surg.
, vol.141
, pp. 1410-1416
-
-
McKellar, S.H.1
Abel, S.2
Camp, C.L.3
Suri, R.M.4
Ereth, M.H.5
Schaff, H.V.6
-
12
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
nd ROCKETAF Investigators
-
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al, and ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
-
(2011)
N Engl J Med.
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
Pan, G.4
Singer, D.E.5
Hacke, W.6
Breithardt, G.7
Halperin, J.L.8
Hankey, G.J.9
Piccini, J.P.10
-
14
-
-
67649562905
-
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomized, double-blind, phase II trial
-
Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet. 2009;374:29-38.
-
(2009)
Lancet.
, vol.374
, pp. 29-38
-
-
Mega, J.L.1
Braunwald, E.2
Mohanavelu, S.3
Burton, P.4
Poulter, R.5
Misselwitz, F.6
Hricak, V.7
Barnathan, E.S.8
Bordes, P.9
Witkowski, A.10
-
15
-
-
84862907587
-
Rivaroxaban in patients with a recent acute coronary syndrome
-
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.
-
(2012)
N Engl J Med.
, vol.366
, pp. 9-19
-
-
Mega, J.L.1
Braunwald, E.2
Wiviott, S.D.3
Bassand, J.P.4
Bhatt, D.L.5
Bode, C.6
Burton, P.7
Cohen, M.8
Cook-Bruns, N.9
Fox, K.A.10
-
16
-
-
45949099359
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
-
DOI 10.1056/NEJMoa0800374
-
Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhoffer E, Misselwitz F, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775. (Pubitemid 351930851)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.26
, pp. 2765-2775
-
-
Eriksson, B.I.1
Borris, L.C.2
Friedman, R.J.3
Haas, S.4
Huisman, M.V.5
Kakkar, A.K.6
Bandel, T.J.7
Beckmann, H.8
Muehlhofer, E.9
Misselwitz, F.10
Geerts, W.11
-
17
-
-
46049106502
-
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
-
RECORD2 Investigators
-
Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
-
(2008)
Lancet.
, vol.372
, pp. 31-39
-
-
Kakkar, A.K.1
Brenner, B.2
Dahl, O.E.3
Eriksson, B.I.4
Mouret, P.5
Muntz, J.6
Soglian, A.G.7
Pap, A.F.8
Misselwitz, F.9
Haas, S.10
-
18
-
-
45949103416
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
-
DOI 10.1056/NEJMoa076016
-
Lassen MR, AgenoW, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786. (Pubitemid 351930852)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.26
, pp. 2776-2786
-
-
Lassen, M.R.1
Ageno, W.2
Borris, L.C.3
Lieberman, J.R.4
Rosencher, N.5
Bandel, T.J.6
Misselwitz, F.7
Turpie, A.G.G.8
-
19
-
-
65549169515
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomized trial
-
RECORD4 Investigators
-
Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, et al, RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. Lancet. 2009;373:1673-1680.
-
(2009)
Lancet.
, vol.373
, pp. 1673-1680
-
-
Turpie, A.G.1
Lassen, M.R.2
Davidson, B.L.3
Bauer, K.A.4
Gent, M.5
Kwong, L.M.6
Cushner, F.D.7
Lotke, P.A.8
Berkowitz, S.D.9
Bandel, T.J.10
-
20
-
-
79957619172
-
Asystematic reviewof rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement
-
Turun S, Banghua L, YuanY, Zhenhui L, YingN, Jin C.Asystematic reviewof rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb Res. 2011;127:525-534.
-
(2011)
Thromb Res.
, vol.127
, pp. 525-534
-
-
Turun, S.1
Banghua, L.2
Yuan, Y.3
Zhenhui, L.4
Ying, N.5
Jin, C.6
-
21
-
-
78650619315
-
Oral rivaroxaban for symptomatic venous thromboembolism
-
EINSTEIN Investigators
-
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-2510.
-
(2010)
N Engl J Med.
, vol.363
, pp. 2499-2510
-
-
Bauersachs, R.1
Berkowitz, S.D.2
Brenner, B.3
Buller, H.R.4
Decousus, H.5
Gallus, A.S.6
Lensing, A.W.7
Misselwitz, F.8
Prins, M.H.9
-
22
-
-
79960068693
-
Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time
-
Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost. 2011;106:156-164.
-
(2011)
Thromb Haemost.
, vol.106
, pp. 156-164
-
-
Mani, H.1
Hesse, C.2
Stratmann, G.3
Lindhoff-Last, E.4
-
23
-
-
77952044405
-
Assessment of laboratory assays to measure rivaroxabanVan oral, direct factor Xa inhibitor
-
Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxabanVan oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-825.
-
(2010)
Thromb Haemost.
, vol.103
, pp. 815-825
-
-
Samama, M.M.1
Martinoli, J.L.2
Leflem, L.3
Guinet, C.4
Plu-Bureau, G.5
Depasse, F.6
Perzborn, E.7
-
24
-
-
78650271337
-
Assays for measuring rivaroxaban: Their suitability and limitations
-
Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit. 2010;32:673-679.
-
(2010)
Ther Drug Monit.
, vol.32
, pp. 673-679
-
-
Lindhoff-Last, E.1
Samama, M.M.2
Ortel, T.L.3
Weitz, J.I.4
Spiro, T.E.5
-
25
-
-
79952301326
-
Apixaban in patients with atrial fibrillation
-
and AVERROES Steering Committee and Investigators
-
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, et al, and AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
-
(2011)
N Engl J Med.
, vol.364
, pp. 806-817
-
-
Connolly, S.J.1
Eikelboom, J.2
Joyner, C.3
Diener, H.C.4
Hart, R.5
Golitsyn, S.6
Flaker, G.7
Avezum, A.8
Hohnloser, S.H.9
Diaz, R.10
-
26
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
ARISTOTLE Committees and Investigators
-
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al, and ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
-
(2011)
N Engl J Med.
, vol.365
, pp. 981-992
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
Lopes, R.D.4
Hylek, E.M.5
Hanna, M.6
Al-Khalidi, H.R.7
Ansell, J.8
Atar, D.9
Avezum, A.10
-
27
-
-
67649563209
-
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
-
APPRAISE Steering Committee and Investigators
-
Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, et al, APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877-2885.
-
(2009)
Circulation.
, vol.119
, pp. 2877-2885
-
-
Alexander, J.H.1
Becker, R.C.2
Bhatt, D.L.3
Cools, F.4
Crea, F.5
Dellborg, M.6
Fox, K.A.7
Goodman, S.G.8
Harrington, R.A.9
Huber, K.10
-
28
-
-
80052162121
-
Apixaban with antiplatelet therapy after acute coronary syndrome
-
APPRAISE-2 Investigators
-
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, et al, APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708.
-
(2011)
N Engl J Med.
, vol.365
, pp. 699-708
-
-
Alexander, J.H.1
Lopes, R.D.2
James, S.3
Kilaru, R.4
He, Y.5
Mohan, P.6
Bhatt, D.L.7
Goodman, S.8
Verheugt, F.W.9
Flather, M.10
-
29
-
-
68249158084
-
Apixaban or enoxaparin for thromboprophylaxis after knee replacement
-
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604.
-
(2009)
N Engl J Med.
, vol.361
, pp. 594-604
-
-
Lassen, M.R.1
Raskob, G.E.2
Gallus, A.3
Pineo, G.4
Chen, D.5
Portman, R.J.6
-
30
-
-
77649113258
-
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomized double-blind trial
-
ADVANCE-2 Investigators
-
LassenMR, RaskobGE, GallusA, Pineo G, ChenD, Hornick P, ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet. 2010;375:807-815.
-
(2010)
Lancet.
, vol.375
, pp. 807-815
-
-
Lassen, M.R.1
Raskob, G.E.2
Gallus, A.3
Pineo, G.4
Chen, D.5
Hornick, P.6
-
31
-
-
78650587760
-
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
-
ADVANCE-3 Investigators
-
Lassen MR, Gallus A, Raskob GE, Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-2498.
-
(2010)
N Engl J Med.
, vol.363
, pp. 2487-2498
-
-
Lassen, M.R.1
Gallus, A.2
Raskob, G.E.3
Lassen, M.R.4
Gallus, A.5
Raskob, G.E.6
Pineo, G.7
Chen, D.8
Ramirez, L.M.9
-
32
-
-
80052502475
-
Chromogenic laboratory assays to measure the factor XaYinhibiting properties of apixabanVan oral, direct and selective factor Xa inhibitor
-
Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH. Chromogenic laboratory assays to measure the factor XaYinhibiting properties of apixabanVan oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183-187.
-
(2011)
J Thromb Thrombolysis.
, vol.32
, pp. 183-187
-
-
Becker, R.C.1
Yang, H.2
Barrett, Y.3
Mohan, P.4
Wang, J.5
Wallentin, L.6
Alexander, J.H.7
-
33
-
-
84872488956
-
-
Accessed October 31, 2011
-
Morton C, Pruthi R, Zhu D, Bergeron B, Ney A, Baumann Kreuziger L, Burnett B, Zantek ND, Dries D, Eginton M. Dabigatran: consensusbased statement on emergency care of bleeding. 2011. Available at: http://www.icsi.org/ guidelines-and-more/protocols-/cardiovascular -protocols/dabigatran-consensus- based-statement-on-emergency- care-of-bleeding-protocol/dabigatran-consensus- based-statement-on- emergency-care-of-bleeding-protocol-63874.html. Accessed October 31, 2011.
-
(2011)
Dabigatran: Consensusbased Statement on Emergency Care of Bleeding
-
-
Morton, C.1
Pruthi, R.2
Zhu, D.3
Bergeron, B.4
Ney, A.5
Baumann Kreuziger, L.6
Burnett, B.7
Zantek, N.D.8
Dries, D.9
Eginton, M.10
-
34
-
-
80052351015
-
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
-
Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31:478-492.
-
(2011)
J Thromb Thrombolysis.
, vol.31
, pp. 478-492
-
-
Wong, P.C.1
Pinto, D.J.2
Zhang, D.3
-
35
-
-
77649221986
-
Hemostatic resuscitation for massive bleeding: The paradigm of plasma and plateletsVa review of the current literature
-
Johansson PI, Stensballe J. Hemostatic resuscitation for massive bleeding: the paradigm of plasma and plateletsVa review of the current literature. Transfusion. 2010;50:701-710.
-
(2010)
Transfusion.
, vol.50
, pp. 701-710
-
-
Johansson, P.I.1
Stensballe, J.2
-
36
-
-
79953163189
-
The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomized controlled trial
-
1101e1-e2 Crash-2 Investigators
-
CRASH-2 Investigators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomized controlled trial. Lancet. 2011; 377:1096-1101, 1101.e1-e2.
-
(2011)
Lancet.
, vol.377
, pp. 1096-1101
-
-
Roberts, I.1
Shakur, H.2
Afolabi, A.3
Brohi, K.4
Coats, T.5
Dewan, Y.6
Gando, S.7
Guyatt, G.8
Hunt, B.J.9
-
37
-
-
84865581160
-
Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients
-
April 27. [ePub ahead of print]
-
Clav A, Fazilleau F, Dumser D, Lacroix J. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patients. Orthop Traumatol Surg Res. 2012 April 27. [ePub ahead of print].
-
(2012)
Orthop Traumatol Surg Res.
-
-
Clav, A.1
Fazilleau, F.2
Dumser, D.3
Lacroix, J.4
-
38
-
-
84856784474
-
Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosisVAmerican College of Chest Physicians evidence-based clinical practice guidelines
-
American College of Chest Physicians
-
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosisVAmerican College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S-e88S.
-
(2012)
Chest.
, vol.141
-
-
Ageno, W.1
Gallus, A.S.2
Wittkowsky, A.3
Crowther, M.4
Hylek, E.M.5
Palareti, G.6
-
39
-
-
80053571188
-
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects
-
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
-
(2011)
Circulation.
, vol.124
, pp. 1573-1579
-
-
Eerenberg, E.S.1
Kamphuisen, P.W.2
Sijpkens, M.K.3
Meijers, J.C.4
Buller, H.R.5
Levi, M.6
-
40
-
-
84858755308
-
The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation
-
van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood. 2011;118:2316.
-
(2011)
Blood.
, vol.118
, pp. 2316
-
-
Van Ryn, J.1
Schurer, J.2
Kink-Eiband, M.3
Clemens, A.4
-
41
-
-
84856214360
-
Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran
-
Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-3599.
-
(2011)
Stroke.
, vol.42
, pp. 3594-3599
-
-
Zhou, W.1
Schwarting, S.2
Illanes, S.3
Liesz, A.4
Middelhoff, M.5
Zorn, M.6
Bendszus, M.7
Heiland, S.8
Van Ryn, J.9
Veltkamp, R.10
-
43
-
-
78649980897
-
Pharmacologic properties of the new oral anticoagulants: A clinician-oriented review with a focus on perioperative management
-
Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des. 2010;16:3436-3441.
-
(2010)
Curr Pharm Des.
, vol.16
, pp. 3436-3441
-
-
Douketis, J.D.1
-
44
-
-
35348879239
-
Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study)
-
DOI 10.1016/j.amjcard.2007.06.034, PII S0002914907014610
-
Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419-1426. (Pubitemid 47576022)
-
(2007)
American Journal of Cardiology
, vol.100
, Issue.9
, pp. 1419-1426
-
-
Ezekowitz, M.D.1
Reilly, P.A.2
Nehmiz, G.3
Simmers, T.A.4
Nagarakanti, R.5
Parcham-Azad, K.6
Pedersen, K.E.7
Lionetti, D.A.8
Stangier, J.9
Wallentin, L.10
-
45
-
-
13244266944
-
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
-
DOI 10.1111/j.1538-7836.2004.00890.x
-
Eriksson BI, Dahl OE, Ahnfelt L, Kä lebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004;2:1573-1580. (Pubitemid 40186173)
-
(2004)
Journal of Thrombosis and Haemostasis
, vol.2
, Issue.9
, pp. 1573-1580
-
-
Eriksson, B.I.1
Dahl, O.E.2
Ahnfelt, L.3
Kalebo, P.4
Stangier, J.5
Nehmiz, G.6
Hermansson, K.7
Kohlbrenner, V.8
-
46
-
-
17644409026
-
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial
-
DOI 10.1111/j.1538-7836.2004.01100.x
-
Eriksson BI, Dahl OE, Bller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, et al, BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103-111. (Pubitemid 41647122)
-
(2005)
Journal of Thrombosis and Haemostasis
, vol.3
, Issue.1
, pp. 103-111
-
-
Eriksson, B.I.1
Dahl, O.E.2
Buller, H.R.3
Hettiarachi, R.4
Rosencher, N.5
Bravo, M.-L.6
Ahnfelt, L.7
Piovella, F.8
Stangier, J.9
Kalebo, P.10
Reilly, P.11
-
47
-
-
35449007749
-
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
-
DOI 10.1111/j.1538-7836.2007.02748.x
-
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, et al, RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185. (Pubitemid 47617868)
-
(2007)
Journal of Thrombosis and Haemostasis
, vol.5
, Issue.11
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
Van Dijk, C.N.5
Frostick, S.P.6
Kalebo, P.7
Christiansen, A.V.8
Hantel, S.9
Hettiarachchi, R.10
Schnee, J.11
Buller, H.R.12
-
48
-
-
34548575058
-
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
-
DOI 10.1016/S0140-6736(07)61445-7, PII S0140673607614457
-
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, et al, RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, doubleblind, noninferiority trial. Lancet. 2007;370:949-956. (Pubitemid 47393577)
-
(2007)
Lancet
, vol.370
, Issue.9591
, pp. 949-956
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
Van Dijk, C.N.5
Frostick, S.P.6
Prins, M.H.7
Hettiarachchi, R.8
Hantel, S.9
Schnee, J.10
Buller, H.R.11
-
49
-
-
57649123692
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
-
RE-MOBILIZE Writing Committee
-
Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, et al, RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
-
(2009)
J Arthroplasty.
, vol.24
, pp. 1-9
-
-
Ginsberg, J.S.1
Davidson, B.L.2
Comp, P.C.3
Francis, C.W.4
Friedman, R.J.5
Huo, M.H.6
Lieberman, J.R.7
Muntz, J.E.8
Raskob, G.E.9
Clements, M.L.10
-
51
-
-
34447317298
-
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study
-
DOI 10.1161/CIRCULATIONAHA.106.668020
-
Agnelli G, Gallus A, Goldhaber SZ, Haas S, HuismanMV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180-187. (Pubitemid 47057524)
-
(2007)
Circulation
, vol.116
, Issue.2
, pp. 180-187
-
-
Agnelli, G.1
Gallus, A.2
Goldhaber, S.Z.3
Haas, S.4
Huisman, M.V.5
Hull, R.D.6
Kakkar, A.K.7
Misselwitz, F.8
Schellong, S.9
-
52
-
-
78650587760
-
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
-
ADVANCE-3 Investigators
-
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-2498.
-
(2010)
N Engl J Med.
, vol.363
, pp. 2487-2498
-
-
Lassen, M.R.1
Gallus, A.2
Raskob, G.E.3
Pineo, G.4
Chen, D.5
Ramirez, L.M.6
-
53
-
-
47649098524
-
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
-
DOI 10.1111/j.1538-7836.2008.03054.x
-
Botticelli Investigators, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313-1318. (Pubitemid 352016310)
-
(2008)
Journal of Thrombosis and Haemostasis
, vol.6
, Issue.8
, pp. 1313-1318
-
-
Buller, H.1
Deitchman, D.2
Prins, M.3
Segers, A.4
-
54
-
-
84860495892
-
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
-
Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D, Ramirez L, Julian J. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10:807-814.
-
(2012)
J Thromb Haemost.
, vol.10
, pp. 807-814
-
-
Levine, M.N.1
Gu, C.2
Liebman, H.A.3
Escalante, C.P.4
Solymoss, S.5
Deitchman, D.6
Ramirez, L.7
Julian, J.8
|